United Therapeutics is down 11.5% since the beginning of the year, and at $318.89 per share, it is trading 22.2% below its 52-week high of $410 from November 2024.

United Therapeutics is highly undervalued with a P/E of 16x and EV/EBITDA of 8.64x, compared to sector medians of 28x and 15.15x, respectively. The company shows strong revenue growth, driven by ...

Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings tomorrow before market open. Here’s what investors should know. United Therapeutics beat analysts’ revenue ...

UNITED THERAPEUTICS ($UTHR) is expected to release its quarterly earnings data on Wednesday, February 26th before market open, per Finnhub. Analysts are expecting ...